INM Stock — InMed Pharmaceuticals Inc.: Cash, EV, Pipeline

What they do

Our research efforts target the treatment of diseases with high unmet medical needs. On March 4, 2026, the InMed Board ratified, confirmed and approved the decision of the board members of BayMedica to wind down and exit BayMedica’s commercial operations business segment, which constitutes the only revenue-generating commercial operations of InMed.

Source: 10-K FY2026 via SEC EDGAR

Share price

$15.56

Market cap

$8.5M

Cash

$1.1M

Enterprise value

$7.4M

Balance sheet

Cash	$1.1M
Debt	$0.0M
Net cash	$1.1M
Enterprise value	$7.4M
Basic shares	5.5M shares
Fully diluted shares	6.2M shares
Fully diluted market cap	$97.1M
Cash per share	$0.21
Quarterly burn	$3.0M
Cash runway	0.8 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

5.5M

Pre-funded warrants

0.0M

Options

0.2M

RSUs

—

Warrants

0.6M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

—

FDSO

6.2M

Cap table as of 2026-09-02.

Price history

Loading INM daily closes…

Loading price history…

Upcoming catalysts

No upcoming catalysts on file for this company.

Full readout calendar →

Pipeline assets

INM-901

Preclinical · Active Modality: small molecule (preferential signaling agonist)

Target CB1/CB2 (also impacts PPAR signaling)

Indications

Alzheimer's disease (Preclinical)

Catalysts

— Q3 2026
— 2027

Status note Disease-modifying candidate with IND-enabling pharmacology and toxicology studies underway.

INM-089

Preclinical · Active Modality: small molecule

Target CB1/CB2

Indications

Dry age-related macular degeneration (Preclinical)

Catalysts

— Early 2027

Status note Preclinical program for dry AMD.

INM-755 (cannabinol)

Stage not disclosed · Active Modality: topical cream

Target CB1/CB2

Indications

Epidermolysis bullosa (Stage not disclosed)

Status note Cannabinol cream. Company does not currently intend to devote significant resources to advancing it; further development would require additional financing.

Per-asset detail extracted from the 10-Q filed 2026-05-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	800,000	+800,000	0.06%	2026-08-14
Vivo Capital	798,377	+798,377	0.11%	2026-08-14
Ikarian Capital	245,025	+245,025	0.06%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

INM — InMed Pharmaceuticals Inc. ☆

What they do

Balance sheet

Share structure

Price history

Upcoming catalysts

Pipeline assets

Specialist fund holders

Latest news

INM — InMed Pharmaceuticals Inc.